MediWound Ltd. (MDWD)

Recent Quarterly Results

Source: Company filings

Price Chart

MediWound Ltd. (MDWD) stock price: $18.48 (+0.06, +0.33%)

Why Bull

• •MediWound's recent insider buying indicates strong confidence from leadership, suggesting they believe in the company's future prospects.
• •The company's innovative treatments for chronic wounds have gained attention, positioning them well in a growing market.
• •Recent positive clinical trial results have bolstered community sentiment, with many seeing the potential for significant advancements in patient care.
• •Social media discussions have shifted positively, reflecting increased optimism among investors and healthcare professionals about MediWound's pipeline.

Why Bear

• •Concerns about the competitive landscape are rising, with several new entrants in the wound care market potentially impacting MediWound's market share.
• •Recent discussions on trading forums highlight skepticism regarding the scalability of their technology in broader applications.
• •Some community members express caution over the company's reliance on a limited product portfolio, raising questions about long-term sustainability.
• •Market sentiment has been tempered by broader economic uncertainties, leading to a cautious approach among investors in the biotech sector.

• Stocks That Hit 52-Week Lows On Monday
  benzinga · Mar 7, 2022

Rationale

AI-generated technical analysis for MDWD including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for MediWound Ltd. (MDWD), choose a timeframe, and track your prediction accuracy.

Current price: $18.48

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 4/100

  Revenue grew only 8.2% YoY, suggesting the company is in a slower growth phase.

• Gross Margin 3/100

  Gross margin of 18.5% is below average, suggesting thin margins and potential pricing pressure.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates MDWD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does MediWound Ltd. do?

MediWound Ltd. is a biopharmaceutical company that develops, manufactures, and commercializes novel bio-therapeutic solutions for tissue repair and regeneration. Its primary product, NexoBrid, is used for the non-surgical removal of eschar in adults with deep partial- and full-thickness thermal burns. The company is also developing EscharEx for chronic wound debridement and MW005 for the treatment of low-risk basal cell carcinoma. MediWound aims to address unmet medical needs in burn care, wound management, and dermatological oncology through its innovative technology platform and pipeline of products.

Is MDWD stock a good buy?

MDWD stock presents a speculative investment opportunity with high potential upside, but also significant risks. The company's lead product, NexoBrid, has shown promise in burn care, and its pipeline of products targeting chronic wounds and skin cancer offers further growth potential. However, MediWound is currently unprofitable, with a negative profit margin of -98.4%, and its financial resources are limited. Investors should carefully consider the company's financial position, clinical trial results, and competitive landscape before investing in MDWD stock. The $0.19B market cap may represent an attractive entry point for risk-tolerant investors.

What are the main risks for MDWD?

MediWound faces several key risks, including the potential failure to obtain regulatory approvals for EscharEx and MW005, which are critical to its long-term growth strategy. Competition from other companies in the wound care and skin cancer markets could also limit its market share and profitability. The company's dependence on the success of NexoBrid makes it vulnerable to changes in the burn care market or the emergence of competing products. Additionally, MediWound's limited financial resources and need for additional funding could constrain its ability to execute its growth plans. Product liability claims and litigation also pose a risk to the company's financial stability and reputation.

Is MDWD a good stock to buy?

Whether MDWD is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the MDWD MoonshotScore?

The MoonshotScore for MDWD is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is MDWD data updated?

MDWD stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to MDWD is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for MDWD?

Growth catalysts for MediWound Ltd. (MDWD) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes MediWound Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are MDWD's main competitors?

MediWound Ltd. (MDWD) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether MDWD has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about MDWD?

Wall Street analyst coverage for MDWD includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is MDWD's market cap?

Market capitalization (market cap) for MDWD is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows MDWD's current market cap alongside enterprise value and other valuation metrics.

How has MDWD stock performed recently?

MDWD's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing MDWD's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in MDWD?

Key risk categories for MDWD include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures MDWD's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling MDWD?

Insider trading activity for MDWD tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is MDWD a good stock for beginners?

MediWound Ltd. (MDWD) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is MDWD for first-time investors?

Every stock carries risk, including MediWound Ltd. (MDWD). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like MDWD.